Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Anti-Cancer Drugs

• Publication date

  2012-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/CAD.0b013e32834e7d9bPMID 23422737
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Improved classification of breast cancer by analysis of genetic alterations and gene expression profiling

  2011cited by this paper
• Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer.

  2011cited by this paper
• Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.

  2010cited by this paper
• Restoration of Gefitinib Efficacy Following Chemotherapy in a Patient with Metastatic Non-Small Cell Lung Cancer

  2010cited by this paper
• Gene Polymorphisms and Chemotherapy in Non-small Cell Lung Cancer.

  2009cited by this paper
• Addition of S-1 to the Epidermal Growth Factor Receptor Inhibitor Gefitinib Overcomes Gefitinib Resistance in Non–small cell Lung Cancer Cell Lines with MET Amplification

  2009cited by this paper
• Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.

  2009cited by this paper
• A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

  2009cited by this paper
• Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer

  2009cited by this paper
• Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study.

  2009cited by this paper
• Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER 2-Positive Breast Cancer

  2009cited by this paper
• Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2

  2009cited by this paper
• Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

  2008cited by this paper
• Lapatinib Resistance in HCT116 Cells Is Mediated by Elevated MCL-1 Expression and Decreased BAK Activation and Not by ERBB Receptor Kinase Mutation

  2008cited by this paper
• A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

  2008cited by this paper
• EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation

  2008cited by this paper
• The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.

  2008cited by this paper
• A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer.

  2008cited by this paper
• Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor

  2008cited by this paper
• Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells.

  2008cited by this paper
• Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

  2007cited by this paper
• 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

  2007cited by this paper
• A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

  2007cited by this paper
• Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.

  2007cited by this paper
• The traditional Chinese herbal compound rocaglamide preferentially induces apoptosis in leukemia cells by modulation of mitogen‐activated protein kinase activities

  2007cited by this paper
• Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer.

  2007cited by this paper
• Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer

  2006cited by this paper
• A Phase I Clinical and Pharmacokinetic Study of Oral CI-1033 in Combination with Docetaxel in Patients with Advanced Solid Tumors

  2006cited by this paper
• Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

  2006cited by this paper
• Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.

  2006cited by this paper
• Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

  2006cited by this paper
• Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells.

  2005cited by this paper
• Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

  2005cited by this paper
• Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

  2005cited by this paper
• Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.

  2005cited by this paper
• Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.

  2005cited by this paper
• Phase 1 Clinical and Pharmacokinetics Evaluation of Oral CI-1033 in Patients with Refractory Cancer

  2005cited by this paper
• Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase

  2004cited by this paper
• Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule

  2004cited by this paper
• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

  2004cited by this paper
• Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression.

  2004cited by this paper
• P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells.

  2004cited by this paper
• Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016

  2004cited by this paper
• P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells

  2004cited by this paper
• Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

  2003cited by this paper
• CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer.

  2003cited by this paper
• Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer.

  2003cited by this paper
• The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.

  2002cited by this paper
• Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.

  2002cited by this paper
• In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2-expressing human breast cancer cell lines.

  2002cited by this paper
• Akt, MAPK (Erk1/2), and p38 Act in Concert to Promote Apoptosis in Response to ErbB Receptor Family Inhibition*

  2001cited by this paper
• Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

  2001cited by this paper
• CI-1033, a pan-erbB tyrosine kinase inhibitor.

  2001cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033

  2001cited by this paper
• The n e w e n g l a n d j o u r n a l of m e d i c i n e

  2001cited by this paper
• Cell signaling by receptor tyrosine kinases.

  2000cited by this paper
• The biochemistry of apoptosis

  2000cited by this paper
• Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.

  2000cited by this paper
• Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.

  1999cited by this paper
• Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

  1999cited by this paper
• Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

  1999cited by this paper
• Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity.

  1994cited by this paper
• Signaling by Receptor Tyrosine Kinases

  1993cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper

• Poziotinib treatment in patients with HER2-positive advanced breast cancer who have received prior anti-HER2 regimens

  2024cites this paper
• Emerging Targeted Therapies for HER2-Positive Breast Cancer

  2023cites this paper
• Targeting Cytotoxic Agents through EGFR-Mediated Covalent Binding and Release

  2023cites this paper
• Novel HER-2 Targeted Therapies in Breast Cancer

  2023cites this paper
• Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations

  2023cites this paper
• A small-molecule pan-HER inhibitor alone or in combination with cisplatin exerts efficacy against nasopharyngeal carcinoma

  2023cites this paper
• Therapeutic strategies for HER2-positive breast cancer with central nervous system involvement: a literature review and future perspectives

  2023cites this paper
• Unlocking New Avenues in Breast Cancer Treatment: The Synergy of Kinase Inhibitors and Immunotherapy

  2023cites this paper
• Head and neck squamous cell carcinoma: Exploring frontiers of combinatorial approaches with tyrosine kinase inhibitors and immune checkpoint therapy.

  2022cites this paper
• Emerging tyrosine kinase inhibitors for head and neck cancer

  2022cites this paper
• Design, synthesis, and in vitro antitumor activity of 6-aryloxyl substituted quinazoline derivatives

  2022cites this paper
• Poziotinib in Non–Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial

  2021cites this paper
• Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells

  2020cites this paper
• Poziotinib and bovine serum albumin binding characterization and influence of quercetin, rutin, naringenin and sinapic acid on their binding interaction.

  2020cites this paper
• New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?

  2020cites this paper
• Synthesis and Evaluation of Some Novel 6-Substituted Quinazoline Derivatives as Antitumor Agents

  2019influential citation
• Challenges and insights of early oncology drug development in the Asia-Pacific region: introduction of phase I oncology clinical trial center and experience sharing for early clinical trials in Seoul National University Hospital, Korea.

  2019cites this paper
• The Design, Synthesis and Preliminary Pharmacokinetic Evaluation of d3-Poziotinib Hydrochloride.

  2019cites this paper
• A phase II trial of the pan‐HER inhibitor poziotinib, in patients with HER2‐positive metastatic breast cancer who had received at least two prior HER2‐directed regimens: results of the NOV120101‐203 trial

  2018cites this paper
• Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

  2017cites this paper
• Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancer

  2016cites this paper
• An Improved Procedure for the Preparation of Poziotinib

  2015cites this paper
• Antitumor Activity of HM781-36B, alone or in Combination with Chemotherapeutic Agents, in Colorectal Cancer Cells

  2015cites this paper
• ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors.

  2014cites this paper
• Development of EGFR family small molecule inhibitors for anticancer intervention: an overview of approved drugs and clinical candidates.

  2014cites this paper
• HER protein-tyrosine kinases : Structures and small olecule inhibitors

  2014cites this paper
• Treating the HER2 pathway in early and advanced breast cancer.

  2013cites this paper